Table 2 Action potential parameters in rabbit Purkinje fiber
From: Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
|  | Control | 3 μM Saxagliptin | 10 μM Saxagliptin | 30 μM Saxagliptin |
|---|---|---|---|---|
Resting Membrane Potential, mV | −84 (1) | −84 (1) | −86 (1) | −85 (2) |
% Change | 0 (0) | 0 (1) | 2 (2) | 1 (3) |
Overshoot, mV | 31 (1) | 29 (4) | 32 (4) | 29 (5) |
% Change | 0 (0) | −7 (12) | 1 (11) | −7 (14) |
Maximum upstroke velocity (Vmax), v/s | 471 (15) | 446 (15) | 462 (21) | 437 (13) |
% Change | 0 (0) | −5 (3) | −2 (3) | −7 (5) |
APD50, ms | 149 (25) | 149 (24) | 153 (26) | 152 (21) |
% Change | 0 (0) | 0 (0) | 2 (1) | 3 (4) |
APD90, ms | 232 (11) | 235 (11) | 237 (14) | 239 (11) |
% Change | 0 (0) | 2 (1) | 2 (1) | 3 (2) |